Abstract
Background aims
Several studies have shown the efficacy of mesenchymal stem cell (MSC) therapy for
lower extremity vascular disease (LEVD) in diabetic patients, but the results are
not consistent. Therefore, the authors conducted a meta-analysis of randomized controlled
trials (RCTs) to examine the safety and efficacy of MSC therapy in diabetic patients
with LEVD.
Methods
Eight available databases were searched in both English and Chinese to identify RCTs
comparing MSC therapy-based conventional treatment with conventional treatment alone
in diabetic patients with LEVD. Three investigators independently screened the literature,
extracted the data and assessed the risk bias. Meta-analysis was performed using RevMan
5.4.1 and Stata 14.0.
Results
A total of 10 studies involving 453 patients were included. Compared with conventional
treatment only, patients receiving MSC therapy-based conventional treatment had a
higher ulcer healing rate, greater number of reduced ulcers and shorter complete healing
time. MSC therapy also increased ankle–brachial index and transcutaneous oxygen pressure.
In addition, four of the included studies showed that MSC therapy significantly improved
the number of new collateral vessels. Moreover, no more adverse events were recorded
in the MSC group.
Conclusions
This meta-analysis suggests that MSC therapy promotes ulcer healing in diabetic LEVD
patients with ulcers, improves blood supply and has a favorable safety profile. More
large and well-designed RCTs with long-term follow-up are still needed to explore
the safety and efficacy of MSC therapy in diabetic patients with LEVD.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update).Diabetes Metab Res Rev. 2020; 36: e3276
- Recent advances on the development of wound dressings for diabetic foot ulcer treatment—a review.Acta Biomater. 2013; 9: 7093-7114
- Risk of lower limb amputation in a national prevalent cohort of patients with diabetes.Diabetologia. 2018; 61: 626-635
- Interventional therapy in diabetic foot: risk factors, clinical events and prognosis at one year follow-up (a study of 103 cases).Pak J Biol Sci. 2012; 15: 789-794
- Guidelines on use of interventions to enhance healing of chronic foot ulcers in diabetes (IWGDF 2019 update).Diabetes Metab Res Rev. 2020; 36: e3283
- Advances in Revascularization for Peripheral Artery Disease: Revascularization in PAD.Circ Res. 2021; 128: 1885-1912
- In vitro osteoblastic differentiation of mesenchymal stem cells generates cell layers with distinct properties.Stem Cell Res Ther. 2018; 9: 203
- In search of the in vivo identity of mesenchymal stem cells.Stem Cells. 2008; 26: 2287-2299
- Mechanisms involved in the therapeutic properties of mesenchymal stem cells.Cytokine Growth Factor Rev. 2009; 20: 419-427
- Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia.Exp Clin Endocrinol Diabetes. 2013; 121: 48-53
- Localization of human adipose-derived stem cells and their effect in repair of diabetic foot ulcers in rats.Stem Cell Res Ther. 2016; 7: 155
- Effect of different transplantations with bone-marrow derived mesenchymal stem cells on diabetic foot ulcers in rats.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013; 38: 347-355
- Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia.Journal of medical colleges of PLA;. 2008; 23: 106-115
- Autologous bone marrow mesenchymal stem cell transplantation for treatment of diabetic foot following amplification in vitro.Chinese Journal of Tissue Engineering Research. 2009; 13: 6227-6230
- Clinical Evaluation of Human Umbilical Cord Mesenchymal Stem Cell Transplantation After Angioplasty for Diabetic Foot.Exp Clin Endocrinol Diabetes. 2016; 124: 497-503
- Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: Phase I/2 safety study.Foot and Ankle Surgery. 2021; 27: 636-642
- Effect and potential mechanism of local injection of umbilical cord mesenchymal stem cells in treatment of diabetic foot.Medical Journal of West China. 2020; 32: 1664-1668
- The clinical study of autologous adipose-derived stem cells(ADSCs) therapy in repairing diabetic foot.Journal of Clinical Surgery. 2018; 26: 63-66
- Umbilical cord mesenchymal stem cell transplantation for treatment of diabetic lower limb vascular disease.Chinese Journal of Tissue Engineering Research. 2014; 18: 3670-3675
- Autologous mononuclear versus mesenchymal stem cells in healing of recalcitrant neuropathic diabetic foot ulcers.Diabetologia. 2018; 61: S7
- Potential of Allogeneic Adipose-Derived Stem Cell-Hydrogel Complex for Treating Diabetic Foot Ulcers.Diabetes. 2019; 68: 837-846
- Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells.Rejuvenation Res. 2009; 12: 359-366
- Mesenchymal stem cells: potential for therapy and treatment of chronic non-healing skin wounds.Organogenesis. 2015; 11: 183-206
- Effects of umbilical cord blood stem cells on healing factors for diabetic foot injuries.Biotech Histochem. 2017; 92: 15-28
- Vascular evaluation and arterial reconstruction of the diabetic foot.Clin Podiatr Med Surg. 2003; 20: 689-708
- Hypoxia preconditioned human adipose derived mesenchymal stem cells enhance angiogenic potential via secretion of increased VEGF and bFGF.Cell Biol Int. 2013; 37: 551-560
- Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo.Sci Rep. 2016; 6: 21961
- Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles.Carcinogenesis. 2020; 41: 100-110
- Adiposederived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells.Oncol Rep. 2019; 41: 2126-2136
- Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy.Int J Mol Sci. 2013; 14: 17986-18001
- Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.Stem Cells. 2006; 24: 1294-1301
- Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer.J Diabetes Res. 2017; 20179328347
- The synergistic effect of electroacupuncture and bone mesenchymal stem cell transplantation on repairing thin endometrial injury in rats.Stem Cell Res Ther. 2019; 10: 244
- Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy.Stem Cells Transl Med. 2017; 6: 689-699
- Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.J Vasc Surg. 2018; 67: 656-661
- Adipose-Derived Mesenchymal Stem Cells in the Treatment of Diabetic Foot Ulcers: A Review of Preclinical and Clinical Studies.Angiology. 2020; 71: 853-863
- Adipose-derived stem cells promote tumor initiation and accelerate tumor growth by interleukin-6 production.Oncotarget. 2015; 6: 7713-7726
- Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy.Cancer Lett. 2016; 375: 349-359
Article info
Publication history
Published online: October 13, 2021
Accepted:
August 14,
2021
Received:
May 27,
2021
Identification
Copyright
© 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
